雷帕鸣(西罗莫司片)有效果吗

Is it effective?

Rapamune (sirolimus tablets, Rapamune) is a prescription drug for use only by physicians experienced with immunosuppressive therapy and managing kidney transplant patients. In clinical trials, the use of rapamune (sirolimus tablets, Rapamune) can effectively prolong the survival of patients after transplantation and reduce the occurrence of acute rejection.

Rapamune (sirolimus tablets, Rapamune) is recommended for use in combination with cyclosporine and corticosteroids, taken orally once daily. To reduce differences in the absorption of rapamycin, patients should choose to take it regularly with or without food. Tablets should not be broken or chewed.

  Experimental studies have found that rapamune (sirolimus tablets, Rapamune) does not inhibit calcineurin after binding to cytoplasmic proteins, so it can completely avoid the nephrotoxicity of calcineurin inhibitors (CNI). It is one of the best choices when liver or renal insufficiency occurs after organ transplantation or when CNI cannot reach the ideal drug concentration.

Rapamune (Sirolimus Tablets, Rapamune) combined with low-dose cyclosporine A is a better immunosuppressive treatment option after renal transplantation, and the use of Rapamune (Sirolimus Tablets, Rapamune) can reduce the dose of CNI. After renal transplantation, it is safe and effective to control the steady-state trough concentration of Rapamune (sirolimus tablets) at 4-8ng/ml or 5-8ng/ml. Rapamune (sirolimus tablets, Rapamune) can also reduce the incidence of non-melanoma skin cancer after kidney transplantation. In addition, rapamycin has also achieved good anti-rejection effects after heart transplantation, lung transplantation, corneal transplantation and other transplants, but the therapeutic concentration has not been reported.

  It can be seen that its use in kidney transplant patients can not only effectively reduce the risk of rejection, but is also relatively safe. However, immunosuppression may also increase the risk of infection, including activation of underlying viral infections (including BK virus-related nephropathy), fatal infections, and sepsis. Patients should be treated prophylactically for Pneumocystis jiroveci pneumonia (PCP) 1 year after transplantation and against cytomegalovirus (CMV) 3 months after transplantation.

Recommended related hot articles: /newsDetail/82382.html